AptaBio Therapeutics Inc. (KOSDAQ:293780)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,300.00
+80.00 (0.97%)
Apr 28, 2026, 3:30 PM KST
12.16%
Market Cap 233.18B
Revenue (ttm) 3.70B
Net Income (ttm) -16.35B
Shares Out 28.09M
EPS (ttm) -607.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 241,842
Average Volume 121,940
Open 8,210.00
Previous Close 8,220.00
Day's Range 7,980.00 - 8,300.00
52-Week Range 6,060.00 - 11,960.00
Beta 0.92
RSI 67.48
Earnings Date May 14, 2026

About AptaBio Therapeutics

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical nee... [Read more]

Sector Healthcare
Founded 2009
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 293780
Full Company Profile

Financial Performance

In 2025, AptaBio Therapeutics's revenue was 3.70 billion, an increase of 10.02% compared to the previous year's 3.36 billion. Losses were -16.35 billion, -44.36% less than in 2024.

Financial Statements

News

There is no news available yet.